



Corporate Presentation

May 2021



SEEKING GENE THERAPY CURES

NASDAQ: RCKT

Important Information

Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket's ongoing trials, our expectations regarding when clinical trial sites will resume normal business operations, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-K for the year ended December 31, 2020, filed March 1, 2021 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Mission, Vision and Values

TRUST



Trust is given and trust is earned – it's a balance. The word trust comes from the Proto-Indo-European word *deru* which means “to be firm, solid, steadfast.” Trust is the ground and foundation for everything we do.

GENEROSITY



Being generous means following up, sharing our best ideas, forgiving ourselves and others, asking who needs us, treating our word as gold, taking time to truly see others, and so many other things. The word generous has the same root as the word “gene” – which meant “to beget.” Genes thrive on the generosity of others. What more is there to say?

CURIOSITY




The wonder of a child staring up at the night sky. Humility, egolessness. No single one of us can do this job alone and it is ok to ask for help. Curiosity is derived from the Latin word “cura” which gave birth to the word “care” as well as “cure.” Generosity is to curiosity what gene is to cure.

ELEVATE




Derived from Latin *levis* which means “light” as opposed to heavy. How can we bring trust, generosity and curiosity to elevate ourselves, each other, the pipeline and ultimately the life experience of patients and their families?

Multi-Platform Gene Therapy Targeting Rare Diseases



Gene Therapy: A Multi-Platform Approach



About Rocket Pharma

**Multi-Platform Gene Therapy
Company Targeting Rare Diseases:
1st-in-class with direct on-target
mechanism of action and clearly-
defined clinical endpoints**

Ex-vivo Lentiviral vectors (LVV)

- Fanconi Anemia (FA)
- Leukocyte Adhesion Deficiency-I (LAD-I)
- Pyruvate Kinase Deficiency (PKD)
- Infantile Malignant Osteopetrosis (IMO)

In-vivo adeno-associated virus (AAV)

- Danon Disease

**Multiple Near- & Medium-
term Company Value Drivers**

Near-term Milestones

- All five programs in the clinic (initiation of IMO)
- New preliminary data in Danon & PKD; Additional mature data in FA & LAD-I
- Two programs in registration-enabling Phase 2 (FA, LAD-I)

Medium-term Milestones

- First global submission (BLA)
- Platform establishment and pipeline expansion
- Current programs eligible for Pediatric Priority Review Vouchers

**Strong Precedents and
World-Class Expertise**

Strong Precedents and Sound Strategy

- Compelling clinical proof-of-concept for LVV- & AAV-based therapies across a spectrum of genetic disorders
- Clearly-defined product metrics across indications
- Experienced company leadership
- Leading research and manufacturing partners

Rocket's Leadership Team



Gaurav Shah, M.D.
Chief Executive Officer
Spearheaded Kymriah (CAR-T-19)
development at Novartis towards approval




Kinnari Patel, Pharm.D., MBA
President and Chief Operating Officer
Led Opdivo and six rare disease indication
approvals



Gayatri R. Rao, M.D., J.D.
Chief Development Officer of LVV, SVP
7-Year Former Director of FDA's Office of Orphan
Products Development



Jonathan Schwartz, M.D.
CMO & Clinical Development, SVP
Led multiple biologics approvals



Claudine Prowse, Ph.D.
SVP, Strategy & Corporate Dev
~20 years capital markets, strategy,
corporate development



Raj Prabhakar, MBA
Chief Business Officer, SVP
~20 years cell, gene and biotech
business development



John Militello, CPA
VP, Principal Accounting Officer
~20 years public company finance and accounting
experience, 6 years biotech experience



Carlos Garcia-Parada, MBA
Chief Financial Officer
14 years of Oncology & Rare Disease experience
Leading role in launching Kymriah, the first CAR-T product on the market.



Ramji Krishnan, Ph.D.
VP, Manufacturing & Manufacturing Sciences
17+ years of CMC product development and life cycle
management expertise




José Trevejo
Chief Development Officer of AAV, SVP
~20 years of clinical development expertise



Brian C. Beard, Ph.D.
AVP, CMC
15+ years cell and gene therapies expertise



Rocket's Expanding Pipeline: Potential for Significant Value Creation Near and Long Term



Fanconi Anemia (FA)

Monogenic DNA-repair disorder

RP-L102

Fanconi Anemia

RP-A501

Danon Disease

RP-L201

Leukocyte Adhesion Deficiency-I


RP-L301

Pyruvate Kinase Deficiency

RP-L401

Infantile Malignant Osteopetrosis

OVERVIEW:



- Current available treatments:** Allogeneic hematopoietic stem cell transplant associated with 100-day mortality, GVHD, and additional increased cancer risk
- Addressable Market²:** Estimated US + Europe target population of approximately 4,000 patients, 500 patients/year
- RP-L102:** LVV gene therapy that elicits phenotypic correction of blood cells and stabilization of previously declining blood counts
- Regulatory Designations:** Fast Track, Regenerative Medicine Advanced Therapy (RMAT) and Rare Pediatric Disease designations in the US; Advanced Therapy Medicinal Product (ATMP) classification and PRiority Medicines (PRIME) in the EU; Orphan Drug designation in the US/EU


¹ Alter Br J Hametol 2010.

² 4,000 based on a detailed population analysis of FA genomic variants. 500 per year extrapolated by actual transplants per year plus patients from prevalence

Potential to Correct Bone Marrow Defect without Conditioning to Prevent Hematologic Failure


Rationale for GTx in FA:

- Somatic mosaicism demonstrates that a **modest number** of gene-corrected hematopoietic stem cells can repopulate a patient's blood and bone marrow with corrected (non-FA) cells.^{1,2}



Gene Therapy Value Proposition:

- Potential to **correct** blood & bone marrow defect **without conditioning**
- GTx implemented as preventative measure to **avert bone marrow failure**; BMT is indicated for patients in whom marrow failure has occurred.



¹ Soulier, J., et al. (2005) Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. *Blood* 105: 1329-1336; ²Data on file: Showing a single patient with a spontaneous correction of blood counts, no therapy administered.

FA Path to Product Registration

CIEMAT-Sponsored FANCOLEN 1 Study Process A

- Interim data (>12-month follow-up) showed evidence of durable engraftment, continued improvement in phenotypic markers and stabilization of previously-declining blood counts
- No conditioning required

OPTIMIZATION

Rocket-Sponsored Process B

*(Optimized CD34 cell enrichment,
transduction enhancers,
commercial-grade vector and
modified cell processing)*

- Clinical trial of ~12 patients with sites at Stanford (US), Niño Jesús Hospital (Spain), and other leading centers in the US/Europe
- No conditioning required

BLA/
MAA

RP-L102 “Process B”: Pivotal Clinical Trials and Outcome Measures

RP-L102 Studies	Non-randomized, open label studies: US Phase 1, US Phase 2, and EU Phase 2 (FANCOLEN-II)	
CMC/Drug Product	“Process B” includes cell enrichment, transduction enhancers, commercial-grade vector and modified cell processing	
Inclusion Criteria	Focus on patients with no/limited marrow failure, optimize preventative potential in absence of conditioning Minimum age: 1; Maximum age: US Ph 1 (12-yrs); US Ph 2 (none); EU Ph 2 (17-yrs) BM CD34+ concentration $\geq 30/\mu\text{L}$ (from aspirate); if BM CD34+ of 10-29/μL, then at least 2 of the following: Hb $\geq 11\text{g/dL}$, ANC $\geq 900/\mu\text{L}$, or Platelets $\geq 60,000/\mu\text{L}$ US Ph 1 only: At least 1 hematologic parameter (Hb, ANC or Plt) below lower limit of normal	
Exclusion Criteria	Available & eligible HLA-identical sibling donor MDS or leukemia (including associated cytogenetic abnormalities) Mosaicism with stable/improved blood counts	
Endpoints	Efficacy Safety of RP-L102	Engraftment: Peripheral blood (PB) and BM vector copy number (VCN) Phenotypic correction: Increased resistance of BM and PB cells to MMC and DEB Clinical response: Prevention of BMF <i>Efficacy in 5 of 12 Patients (observed over 1-3 years post rx) required to reject null hypothesis</i>

RP-L102 Treated Study Patients

Phase	Subject #	Site	Age at Enrollment	Gender	Follow-up
PHASE 1	1 (1001)	US	5	F	24M
	2 (1002)*	US	6	F	18M
PHASE 2	3 (2004)	Spain	3	M	15M
	4 (2008)	Spain	2	F	6M
	5 (2009)	Spain	3	M	6M
	6 (2010)	US	3	M	6M
	7 (2011)	US	5	F	6M
	8 (2014)	UK	6	F	4M
	9 (2016)	US	2	M	4M

- 9 subjects treated across 3 clinical sites, 2 under US Phase 1 and 7 under global Phase 2
- All subjects ≤ 6 years at enrollment
- 6 subjects have ≥ 6 months of follow-up; 1 subject withdrawn from the study; 2 remaining subjects treated more recently with more limited follow-up
- Note: Follow-up has been challenged by COVID-19 pandemic

* Subject withdrawn from the study at 18 months post-RP-L102 infusion; received successful allogeneic HSCT

RP-L102 Investigational Product Metrics

Phase	Subject #	CD34+ Cells/kg	CFCs/kg	Mean VCN: Liquid Culture	Mean VCN: CFCs	Transduction Efficiency (%)	CFC Survival MMC 10nM (%)	Overall DP metrics are consistent with the more optimally treated subjects from FANCOLEN-I study Mean values: VCN (liq) 1.95 VCN (CFC) 0.87 TD efficiency 81% CFC MMC-res 49% Overall transduction and MMC-resistance levels in DP are consistent with high degree of corrected HSPCs
PHASE 1	1 (1001)*	2.0 x 10 ⁵	5.2 x 10 ⁴	2.08	0.62	67	33	
	2 (1002)*	3.7 x 10 ⁵	5.0 x 10 ⁴	2.21	0.92**	72	47	
PHASE 2	3 (2004)	4.8 x 10 ⁵	1.1 x 10 ⁵	1.70	0.73	100	63	
	4 (2008)	3.2 x 10 ⁶	2.8 x 10 ⁵	1.65	1.56	97	63	
	5 (2009)	1.9 x 10 ⁶	1.5 x 10 ⁵	2.16	0.76	61	45	
	6 (2010)*	4.1 x 10 ⁶	n/a	0.62	n/a	n/a	n/a	
	7 (2011)*	2.8 x 10 ⁶	n/a	1.46	n/a	n/a	n/a	
	8 (2014)*	5.4 x 10 ⁵	3.6 x 10 ⁴	3.68	pending	pending	31	
	9 (2016)*	3.0 x 10 ⁵	2.5 x 10 ⁴	1.96	0.64	88	64	

*Mean CFC VCN was assessed from a cryopreserved drug product sample.

**Per NC200 automated count (results in ~50% lower count vs. manual used in FANCOLEN-I).


Data as of May 2021. "Optimally" means of the nine patients treated in Fancolen-I the two that had the best benefit risk

CFCs: colony forming cells
VCN: vector copy number
MMC: mitomycin-C




RP-L102 Treated Study Patients (>12M Follow-up)

Subject 1 (1001)



Subject 3 (2004)



Increasing BM progenitor resistance to 10 nM MMC seen in both subjects


- Subject 1: 16% at 2 years* post-RP-L102 infusion
- Subject 3: 29% at 1 year post-RP-L102 infusion

- Sustained increasing VCN in PB mononuclear cells and evidence of gene markings in BM seen in both subjects with ≥12 months of follow up
- Previously declining blood counts across multiple lineages appear to have stabilized in Subject 3; Subject 1 has not required any transfusion support

Data as of May 2021. *BM CFC MMC resistance assay was not performed at study's centralized laboratories

‡ Data point has not yet been monitored

RP-L102 Study Subjects with ≥ 6 mo Follow Up



At 6 months post-RP-L102 treatment, Subjects 4 and 5 have early evidence of BM progenitor resistance (25% and 14% respectively) to 10 nM MMC, consistent with BMMC VCN;

All subjects have demonstrated progressive increases in PB VCN and blood count stability

Data as of May 2021. *6-month BM assessment deferred due to COVID-19 travel concerns

Summary of Pivotal RP-L102 Treated Study Patients

PB VCN available for N = 9
7 of 9 showed preliminary evidence of engraftment

N = 6 with $\geq 6M$ VCN

- 6 of 7 showed increasing evidence of engraftment
- 1 patient's course (1002) complicated by *Influenza B* infection; required BMT

N = 1 with early VCN

showed detectable VCN at early follow-up

- All patients clinically stable post-treatment; the patient who required BMT underwent transplant at 18-months and engrafted without complications
- RP-L102 related SAEs: 1 transient infusion-related reaction (Grade 2)
- Patient enrollment and follow-up has been challenged by COVID-19 pandemic

RP-L102 Conclusions: Optimized “Process B” Appears to be a Consistent and Reproducible Improvement over “Process A”

- **9 patients treated** with “Process B”
- Safety results appear **highly favorable**
 - Patients treated without conditioning
 - No signs of dysplasia or other concerning features
 - RP-L102 related SAEs: 1 transient infusion-related reaction (Grade 2)
- Increasing evidence of **engraftment** observed in **6 out of 7 patients followed for 6 months or longer**
 - 1 patient’s course complicated by Influenza B resulting in progressing BMF; successfully received BMT at 18-months
 - 1 of 2 patients with <6M of follow-up with detectable VCN
- Increasing BM CFC MMC-resistance seen in 4 subjects*

*** Efficacy activity in 5 of 12 patients (observed over 1-3 years post rx) required to reject null hypothesis**



Danon Disease

Monogenic Heart Failure Syndrome

RP-L102
Fanconi Anemia

RP-A501
Danon Disease

RP-L201
Leukocyte Adhesion Deficiency-I


RP-L301
Pyruvate Kinase Deficiency

RP-L401
Infantile Malignant Osteopetrosis

OVERVIEW:

-  **Background:** Devastating *multisystemic disorder* caused by highly penetrant and X-linked dominant *LAMP2 mutations*, rapidly progressive cardiomyopathy is predominant cause of morbidity and early mortality in adolescents & young adults
-  **Currently available treatments:** *Non-curative* heart transplants associated with considerable morbidity and mortality
-  **Addressable Market:** Estimated US + Europe prevalence of *15,000-30,000*
-  **RP-A501:** AAV9 gene therapy product that elicits *improvements in survival*, cardiac function, and liver enzymes in preclinical studies
-  **Regulatory Designations:** Orphan Drug, Rare Pediatric & Fast Track designations in the US

An Impairment in Autophagy Caused by *LAMP2B* Mutations




Epidemiology and Market Opportunity

Hypertrophic Cardiomyopathy (HCM)

- US HCM Prevalence: 600K-1MM+*
- 1-4% of HCM patients consistently identified with LAMP2 mutations in multiple studies with >1000 subjects evaluated**
- Danon Disease Patients with HCM: ***
 - 85% of males
 - 30% of females

Dilated Cardiomyopathy (DCM)

- Danon Disease Patients with DCM ***
 - 15% of males
 - 50% of females



- Hypertrophic Cardiomyopathy
- Dilated Cardiomyopathy
- Other

* J Am Coll Cardiol. 2015 Mar 31;65(12):1249-1254.

** Heart. 2004 Aug;90(8):842-6. N Engl J Med. 2005 Jan 27;352(4):362-72. Genet Med. 2015 Nov;17(11):880-8. Gene. 2016 Feb 15;577(2):227-35. J Cardiovasc Transl Res. 2017 Feb;10(1):35-46

*** Neurology. 2002 Jun 25;58(12):1773-8. Genet Med. 2011 Jun;13(6):563-8. Rev Esp Cardiol (Engl Ed). 2018 Aug 11.


Danon Disease Causes 1-4% of Hypertrophic Cardiomyopathy: Consistent Presence in Multiple Series Published 2004-Present

Author & Year	Age	n HCM	n Danon	% Danon	Note
Charron 2004	N.A.	197	2	1.0%	Studied LAMP2 mutations in 197 HCM patients at a general hospital in Paris
Arad 2005	12-75	75	2	2.7%	Studied glycogen storage diseases in 75 consecutive pts diagnosed with HCM (multicenter US/EU). No cases of Pompe or Fabry were detected.
Yang 2005	1m-15y	50	2	4.0%	Studied LAMP2 mutations in 50 pts with ped./juvenile onset HCM (single US center). Additional DD identified in relatives of the n=2 probands were not included in this analysis.
Cheng 2012	N.A.	50	3	2.3%	Studied LAMP2 mutations in 50 consecutive pts diagnosed with concentric LVH at a general hospital in Peking. (Concentric LVH is seen in appx. 38% of HCM). DD incidence higher (3/36) when n=14 w/ cardiac amyloidosis were removed from n=50 cohort.

Charron et al. Heart 2004; 90:842-6.
 Arad et al. N Engl J Med 2005; 352:362-72.
 Yang et al. Circulation 2005; 112:1612-17.
 Cheng et al. Eur Heart J 2012; 33:649-56.

RP-A501 Restores Cardiac Function in KO Mice


Dose-Dependent Improvements in Systolic and Diastolic Function in LAMP2 KO Mice



Lower dP/dt max indicates impaired contractility; Higher (less negative) dP/dt min indicates impaired heart relaxation

*PBS = Phosphate Buffered Saline (Negative Control)


RP-A501 Shows Survival Benefit at Higher Doses in Preclinical Studies




Note: All mice were sacrificed at Month 10

Protein: RP-A501 Elicits Durable Expression of LAMP2B Protein and Autophagy in Heart¹


LAMP2 PROTEIN EXPRESSION



LC3-II PROTEIN EXPRESSION




WESTERN BLOT




¹Data are Mean $\pm$ SEM. N=5-8 per group. Untx = Untreated, PBS = Phosphate buffered saline
Note: Mouse LAMP2 and Human LAMP2 data are from separate Western blots.

Structural: RP-A501 Reduces Autophagic Vacuoles in All KO Mouse Models



Dose-dependent LAMP2 Expression in Cardiac Tissue



AAV9 Vector Shows Consistent Cardiac Tropism in Several Studies Across Different Species

DISORDER & VECTOR	DOSE	SPECIES	RESULTS	SPONSOR	REFERENCE
LGMD2A AAV9.hCAPN3	3E+13 vg/kg	NHP	8-80-fold higher transduction in cardiac vs. skeletal muscle	Genethon	Lostal (ASGCT 2018)
Non-specific AAV9.Luc	3E+12 vg/kg	NHP	~ 10-fold higher transduction in cardiac vs. diaphragm; and comparable to other muscle	UNC	Tarantal 2016
Pompe AAV9.hGAA	1E+11 vg/mouse	Mouse	~ 10-fold higher transduction in cardiac vs. diaphragm	U. Florida	Falk 2015
DMD AAV9.mDys	1.9 - 6.2E+14 vg/kg	Dog	2-3 fold higher transduction in cardiac vs. skeletal muscle	U. Missouri	Yue 2015
SMA AAV9.SMN	3E+14 vg/kg & 1E+13 vg/kg	Mouse & NHP	~ 100-fold higher transduction in cardiac vs. skeletal muscle (mouse)	Nationwide Children's	Meyer 2014
MPSIIIB AAV9.hNAGLU	1 - 2E+13 vg/kg	NHP	≥ 10-fold higher transduction in cardiac vs. skeletal muscle in majority of animals	Nationwide Children's	Murrey 2014
Non-specific AAV9.Luc	5E+10 vg/mouse	Mouse	5-10-fold higher transduction in cardiac vs. skeletal muscle	UNC	Pulicherla 2011
Pompe AAV9.hGAA	4E+05 - 4E+08 vg/mouse	Mouse	~ 8-12-fold higher transduction in cardiac vs. skeletal muscle or diaphragm	U. Florida	Pacak 2006
SMA AAV9.SMN	2E14 vg/kg	Human	Heart VCN ~3-4, Muscle & CNS ~1	AveXis	Kaspar 2019 (ASGCT 2019)

Summary of Preclinical Data

- Shows Phenotypic Improvements at Low-Dose 5e13 vg/kg:
 - **Survival** benefit at higher doses
 - Dose-dependent **restoration** of cardiac function
 - Improvement in transaminases
- RP-A501 **Reduces** Autophagic Vacuoles in All Examined Organs: Heart, Liver, Skeletal Muscle
- RP-A501 Elicits **dose-dependent increase** in LAMP2 mRNA and protein
- RP-A501 Preclinical Safety, Tox and Biodistribution Summary:
 - No therapy-related deaths
 - No significant hematologic changes
 - No significant biochemical changes
 - No significant clinical chemistry changes
 - Mild and transient ALT elevation that self-resolved after one week in a single NHP
 - In both mouse and NHPs, VCN detection in Danon disease organs indicated high *LAMP2B* presence in heart tissue (for NHP, ~10x higher on average than in skeletal muscle and CNS)

RP-A501 Clinical Trial and Outcome Measures

Non-Randomized Dose-Escalation Phase 1 Study

Study Design

- Phase 1 open label study in male Danon patients
- Two age cohorts
 - Adolescent/Adult (>15 y)
 - Pediatric (8-14 y)
- Treatment doses
 - Low 6.7×10^{13} GC/kg
 - Higher 1.1×10^{14} GC/kg¹

Primary Outcomes

- Assessment of:
 - Safety at all doses
 - Target tissue transduction & LAMP2B expression
 - Effect on cardiomyocyte histology
 - Clinical stabilization or improvement via cardiac imaging, serology and exercise testing

1. IND enables doses up to 2.0×10^{14} GC/kg
<https://clinicaltrials.gov/ct2/show/NCT03882437?cond=danon+disease&draw=2&rank=2>


Natural History of Rapidly Progressing Heart Failure

Cardiac Clinical Features

- Progressive hypertrophic cardiomyopathy/heart failure
- Key Clinical Biomarker Changes
 - Echo:
 - Worsening diastolic parameters
 - ↑ left ventricular end diastolic diameter (LVEDD)
 - ↓ left ventricular fractional shortening (LVFS)
 - ↑ ventricular wall thickness
 - ↓ left ventricular ejection fraction (LVEF) is late event
 - Hemodynamics: Decreasing cardiac output and/or stroke volume
 - Biomarkers: Elevated BNP, CK-MB, troponin

Female Danon Cardiac Histology Suggests Broad LAMP2 Expression Important for Reversal of Phenotype

- Immunohistochemistry (IHC) from Danon female patients with severe disease display large patches negative for LAMP2 expression
- Broad expression of LAMP2 is likely the key to correcting phenotype rather than overall protein levels
- Based on this data, IHC demonstrating broad and *homogeneous cardiac expression may be the best predictor of long-term efficacy*



Cardiac IHC Staining in Female Danon Patient
Requiring Transplant at 10 y¹

RP-A501: Subject Characteristics & AAV Vector Dose


Patient ID	Age at Treatment	Dosing Weight	Cohort Dose	Total Dose
1001	17 y	52.2 kg	6.7×10^{13} GC/kg	3.25×10^{15} GC
1002	20 y	89.1 kg	6.7×10^{13} GC/kg	5.97×10^{15} GC
1005	18 y	91.8 kg	6.7×10^{13} GC/kg	6.08×10^{15} GC
1006	21 y	82.7 kg	1.1×10^{14} GC/kg	9.10×10^{15} GC
1007	20 y	96.7 kg	1.1×10^{14} GC/kg	1.06×10^{16} GC

RP-A501 Demonstrated a Manageable Safety Profile

- In Low-dose cohort, RP-A501 was generally well tolerated with manageable safety profile
 - **Transient** and **reversible** decline in platelets
 - **Transient** and **reversible** transaminase elevation
- In Higher-dose cohort, a single patient experienced drug-related SAE related to complement activation
 - Patient with enhanced risk due to high weight & vector dose and pre-existing AAV immunity
 - Anticipated SAE of atypical hemolytic-uremic syndrome (aHUS) resulting in reversible thrombocytopenia and acute kidney injury (AKI)
 - AKI required supportive care including eculizumab and transient hemodialysis with full return to baseline kidney function within 2-3 weeks
- ***All patients have fully recovered from immune-related sequelae***



RP-A501 Low Dose: DNA Vector Copy Number



* Clinical course and VCN drop suggest apparent poor compliance with steroid regimen

** 1001, 1002 Month 12; 1005 Month 9

RP-A501 Low Dose Cohort Demonstrates Robust Cardiac Expression as Measured by LAMP2 Immunohistochemistry (IHC)


Patient	LAMP2B Relative Expression vs. Control*		
	Regimen	Week 8	Long Term
1001	Steroids only (limited compliance)	7.8%	<15% ¹
1002	Steroids only (local monitoring)	36.9%	67.8% ^{1*}
1005	Steroids → Tacrolimus	17.6%	92.4% ²

- Endomyocardial biopsies were obtained and stained for LAMP2. Percent area of cell staining was quantitated using software in a blinded fashion and expression compared to normal heart tissue. Values represent average of 3-14 sections. Qualitative assessment reported for samples with high variance.


* Preliminary Month 12 update for pt 1002 shows IHC of 78% upon reanalysis

- Sample obtained at Month 12
- Sample obtained at Month 9


RP-A501 Low Dose: Patients 1002 and 1005 Demonstrate Robust Cardiac Expression of LAMP2 by IHC Through Months 9 and 12, Respectively




1002 Baseline



1002 Month 12



1005 Month 9




Normal Heart Control

RP-A501 Low Dose: Endocardial LAMP2B Protein Expression

Patient	Relative LAMP2B Expression vs. Normal By Western Blot	
	Week 8	Long Term
1001	20.7%	17.9% ¹
1002	27.3%	-
1005	42.8%	61.1% ²

1. Sample obtained at Month 6
2. Sample obtained at Month 9


RP-A501 Low Dose Improves or Stabilizes Key Cardiac Marker of Heart Failure: B-type Natriuretic Peptide (BNP)




**Preliminary 18 month update for 1002 is BNP of 200*

RP-A501 Electron Microscopy of Cardiac Myocytes Demonstrates Marked Decrease in Vacuolar Pathology: **Patient 1005**


Baseline



Week 8



Month 9



RP-A501 Low Dose Confers Improvement in Cardiac Output Based on Invasive Hemodynamics in Patients 1002 and 1005

Cardiac Output (L/min)

Patient	Baseline	Long Term ¹
1001	5.2	4.12 ²
1002	3.58	5.8 ² (1.62x increase)
1005	4.5	6.08 ³ (1.35x increase)

1. Calculated Stroke Volume: 40% increase in Patient 1002 and 31% increase in Patient 1005

1001 and 1005 NYHA Class II is stable, and in 1002 NYHA class improved from II to I

2. Sample obtained at Month 12

3. Sample obtained at Month 9

RP-A501 Low Dose: Safety & Efficacy Findings (n=3)

- Generally, **well tolerated** with manageable safety profile in all low-dose patients
- **LAMP2B gene expression** demonstrated in cardiac biopsies from all patients
- **Enhanced cardiac expression** by IHC and Western blot in both patients whose compliance with transient immunosuppressive regimen was closely monitored
 - Consistent increases in percentage and level of IHC staining at later (9-12m) timepoints
- **Positive trends** in key biomarkers and efficacy endpoints
 - Qualitative improvement of vacuolar pathology
 - Clinical lab markers demonstrated improvement in patients 1002 and 1005
 - Trends towards stabilization and/or improvement in cardiac output
- **Benefit observed in all three patients** serves as clinical proof of concept as *Danon disease patients generally do not improve independently*

Leukocyte Adhesion Deficiency-I (LAD-I)

Monogenic Immunodeficiency Disorder

RP-L102
Fanconi Anemia


RP-A501
Danon Disease

RP-L201
Leukocyte Adhesion Deficiency-I

RP-L301
Pyruvate Kinase Deficiency

RP-L401
Infantile Malignant Osteopetrosis

OVERVIEW:



Background: Disorder characterized by recurring and ultimately fatal infections caused by *ITGB2* gene mutations

- >50% patients with severe variant: **60-75% mortality by age 2**



Current Available Treatments: Allogeneic hematopoietic stem cell transplant associated with significant graft failure and acute GVHD



Addressable Market: Estimated **25-50 pts** treatable per year for severe population; up to 100 for potential expansion into moderate population in the US + Europe with effective gene therapy



RP-L201: Preclinical studies show stable engraftment and phenotypic correction in murine models, with restored neutrophil migration capability



Regulatory Designations: Fast Track and Rare Pediatric Disease designations in the U.S.; Advanced Therapy Medicinal Product (ATMP) classification in EU; Orphan Drug designation in the U.S./EU

¹ Defective expression of β_2 integrin on leukocytes limits their extravasation to inflamed sites.

LAD-I Program Summary

Ultra-rare Disease = Streamlined Regulatory Approach

Potential design & clinical endpoints:

- **Target Patient Population:** Severe LAD-I patients (CD18<2%), ~2/3 mortality by 2y
- **Control:** Literature review of ~300 pts. (Rocket/academic collaborative publication¹)
- **Potential Clinical Endpoints:** Modest correction of CD18 expression, survival

Efficacy Trials & Registration Status – Ahead of Schedule

Registration & study planning on-schedule:

- ✓ Orphan Drug (US/EU) and Pediatric Rare Disease (US) designations granted
- ✓ IND & Phase 1/2 cleared by FDA
- ✓ Spain IMPD cleared
- ✓ US PI (UCLA Dr. Don Kohn)
- ✓ Recruitment underway from around the globe
- ✓ 3 global sites planned in the US/EU

Product/Manufacturing Optimization


Process now optimized:

- ✓ VCN using GMP vector with transduction enhancers consistently ~3 (Target VCN >1)

¹Almarza Novoa E, Kasbekar S, Thrasher AJ, Kohn DB, Sevilla J, Nguyen T, Schwartz JD, Bueren JA. Leukocyte adhesion deficiency-I: A comprehensive review of all published cases. J Allergy Clin Immunol Pract. 2018 Jan 20. pii: S2213-2198(17)31026-7. doi: 10.1016/j.jaip.2017.12.008.

Rationale for Gene Therapy in LAD-I: CD18 Expression Correlates to Patient Survival

Kaplan-Meier Survival Estimates by Neutrophil CD18 Expression
-Patients with moderate LAD-I not receiving allogeneic HSCT-




Natural history studies show the **correlation** between **higher CD18** expression and longer patient **survival**, supporting gene therapy's potential in LAD-I patients

The grey diamond indicates the 39% survival to age 2 years for 66 evaluable patients with severe LAD-I not receiving HSCT

LAD-I: Mouse Study Shows LAD-I Correction

- Primary and serially transplanted LAD mice underwent CD18 lenti GTx with different promoters
- Myeloablative conditioning was used
- Rocket chose the Chimeric cFES/CTSG (myeloid-specific) promoter (Post-transplant PB VCN 0.4-0.9)



RP-L201 (LAD-I) Clinical Trial and Outcome Measures¹

Non-Randomized Phase 1/2 Study

Design

- Enroll 9 pediatric patients globally
 - Phase 1: Enroll two patients to assess safety and tolerability
 - Phase 2: Overall survival at multiple sites (US and Europe) n=7

Primary Outcomes

- Phase 1:
 - Safety associated with treatment
- Phase 2:
 - Survival: proportion of patients alive at age 2 and at least 1-year post infusion (without HSCT)
 - Safety associated with treatment

Secondary Outcomes


- Percentage of patients with at least 10% neutrophil CD18 expression
- Percentage of patients with at least 0.1 peripheral WBC gene marking (VCN) at 6 months post-infusion
- Incidence and severity of infections
- Improvement in neutrophilia
- Resolution (partial or complete) of any underlying skin rash or periodontal abnormalities

¹Source: <https://clinicaltrials.gov/ct2/show/NCT03812263?cond=Leukocyte+Adhesion+Deficiency&rank=5>

RP-L201: Subject and Cell Product Characteristics


Patient ID	Gender	Age (enrollment)	Drug Product VCN	CD34+ Cell Dose
1001	F	9 yrs.	3.8	4.2×10^6 /kg
1004	F	3 yrs.	2.5	2.8×10^6 /kg
2005	F	2 yrs.	1.8	6.5×10^6 /kg
2006	M	7 mo.	2.9	4.3×10^6 /kg
2007	M	3y	3.6	5.0×10^6 /kg
2008	M	5m	3.8	3.3×10^6 /kg
2009	M	3y	2.0	4.5×10^6 /kg

RP-L201: CD18 Expression in PB Neutrophils




* Shipping delays (2° to COVID pandemic) may cause under-representation of results
Dim/weak CD18 expression reported at baseline for pt 1004 in ~60% of cells

RP-L201: VCN in PBMCs




PBMC: peripheral blood mononuclear cell

RP-L201: Hematopoietic Recovery in Initial 2 Patients



Data as of May 2021
LAD has received CIRM Funding

Pre-Gene Therapy Medical History of Patient 1001



Historical patient records collected by UCLA Mattel Children's Hospital
LAD has received CIRM Funding

Patient 1001: Visible Improvements Post-Treatment

Pre GTx: Severe infections ≥ 1 per year; numerous hospitalizations, severe skin lesions, continuous prophylactic antibiotics and required home schooling

Post GTx: No infections or hospitalizations, off antibiotics and able to attend school

Spontaneous Abdominal Lesion



**Baseline
(Pre-Treatment)**



**3-months
(Post-Treatment)**



**6-months
(Post-Treatment)**




**12-months
(Post-Treatment)**

Pre-Treatment Medical History of Patient 1004

3-y.o. female


- Delayed umbilical cord separation
- Diagnosed with LAD-I at age 3
- 2 younger siblings diagnosed LAD-I



Pre-Treatment Medical History of Patient 2005


2-y.o. female at enrollment

- Diagnosed with LAD-I at age 2
- 2 older siblings diagnosed with severe LAD-I



Historical patient records collected by UCLA Mattel Children's Hospital

Pre-Treatment Medical History of Patient 2006



Historical patient records collected by UCLA Mattel Children's Hospital



RP-L201 Study Summary

- **Four severe LAD-I patients have been successfully infused with RP-L201 with at least 3-months of follow-up**
- **Safety profile of RP-L201 appears favorable:**
 - Infusion well tolerated; no drug product-related SAEs or severe AEs
- **Preliminary efficacy evident in 4 of 4 patients**, including 2 patients with ≥ 9 -months of follow-up
 - Patient 1001 with durable CD18+ PMN expression $\sim 40\%$ at 18-months and PB VCN of 1.2 at 12-months post-infusion and resolution of pre-existing skin lesions
 - Patient 1004 with CD18+ PMN expression at 28% 9-months post-treatment and early PB VCN were 0.75 with kinetics similar to those of the first patient at 6-months post-treatment
 - Each of initial 4 pts with CD18 expression and VCN consistent with reversal of severe LAD-I phenotype.
- Commercial-grade drug product and centralized testing for all patients treated
- **Enrollment Complete**

Pyruvate Kinase Deficiency (PKD)

Monogenic Red Blood Cell Hemolytic Disorder

RP-L102
Fanconi Anemia


RP-A501
Danon Disease

RP-L201
Leukocyte Adhesion Deficiency-I

RP-L301
Pyruvate Kinase Deficiency

RP-L401
Infantile Malignant Osteopetrosis

OVERVIEW:



Current Available Treatments: *Chronic* blood transfusions and splenectomy—side effects include iron overload and extensive *end-organ damage*



Addressable Market²: ~250-500 patients/year



- Conservative estimates conclude a number from **3,000** to **8,000** in the US + Europe combined



RP-L301: *Improvements in multiple disease components* in a PKD mouse model, including increased hemoglobin, reduced reticulocytosis, resolved splenomegaly and reduced hepatic erythroid clusters and iron deposits

Regulatory Designations: Fast Track in the US and Orphan Drug designation in the US/EU

¹One glucose molecule is metabolized into two Phosphoenolpyruvate and ultimately two Pyruvate (pyruvic acid) molecules; this final enzymatic step yields two additional ATPs from each glucose molecule

²Market research indicates the application of gene therapy to broader populations could increase the annual market opportunity from approximately 250 to 500, based on an estimated prevalence in the US/EU of approximately 3,000 to 8,000.

Preclinical Studies Demonstrated Safety and Efficacy of Lentiviral-mediated Gene Therapy

PKD mice transplanted with gene-corrected cells demonstrated phenotypic correction:

- Significant increase in RBC count and half-life
- Decreased erythropoietin levels
- Normalized spleen and liver size & structure, with no evidence of erythroid clusters or iron deposits
- Improvement in red cell pyruvate kinase enzymatic pathway as assessed by metabolomic assays



Favorable Safety Results:

- No physical, behavioral biochemical, hematologic or morphologic abnormalities observed in transplanted mice
- Limited evidence of PGK-coRPK-WPRE in nonhematopoietic organs, indicating very low risk of germline transmission
- No evidence of replication competent lentivirus (RCL)

Garcia-Gomez et al. 2016; 24(7): 1187 -1198
Min-Oo, et al. Nat Gene. 2003; 35(4): 357-362.
Min-Oo, et al. Genes Immun. 2004; 5(3): 168-175.

RP-L301: Global Phase 1 PKD Gene Therapy Study

Primary Endpoint

Safety and toxicity of RP-L301

Key Secondary Endpoints

- Clinically significant reduction of anemia
- **Transfusion independence** (when relevant) at 12-months
- Achievement of 50% reduction in transfusion requirements (when relevant) at 12-months
- **PB and BM** genetic correction as demonstrated by VCN
- Reduction of hemolysis

Key Eligibility Criteria

Inclusion:

- PKD diagnosis with a confirmed *PKLR* mutation
- Age:
 - 1st cohort (N=2): ≥18 to 50-years
 - 2nd cohort (N=2): ≥12 to 17-years
 - 3rd cohort (N=2): ≥ 8 to 11-years
- **Severe and/or transfusion-dependent anemia**
- Prior splenectomy
- Adequate cardiac, pulmonary, renal and hepatic function

Clinical Sites:

- Hospital Universitario Fundación Jiménez Díaz, Madrid
- Stanford University, Palo Alto, California
- Hospital Infantil Universitario Niño Jesús, Madrid

RP-L301: Patient Characteristics and Product Metrics

Patient Characteristics

Patient	Age (y) and Gender	Hemoglobin (g/dL)	Bilirubin (mg/dL)	Erythropoietin (mIU/mL)	Transfusion Requirement for 2 Years Prior to Enrollment
1001	31 F	7.4 [†]	13.4 mg/dL	35.6 mIU/mL	~14 transfusion episodes
1002	47 M	7.0 [‡]	7.4 mg/dL	57.2 mIU/mL	~5 transfusion episodes


Product Metrics

Patient	CD34+ Cells/kg	Mean VCN: Liquid Culture
1001	3.9 x 10 ⁶	2.73
1002	2.4 x 10 ⁶	2.08

[†] Average hemoglobin calculated over 2-years prior to study enrollment

[‡] Average hemoglobin calculated over 2-years prior to study enrollment; patient has declined red blood cell transfusions

RP-L301: Preliminary Efficacy Results—Patient 1001




- Marked hemoglobin improvement ~7.4 g/dL to 13.9 g/dL (over 9 months post-infusion)
- No transfusion requirements following engraftment

* Lab Values during mobilization/apheresis & post-conditioning period were not included


Data as of April 2021

RP-L301: Preliminary Efficacy Results—Patient 1001


At 1–9 months post RP-L301 *




Sustained reduction in reticulocytes




Erythropoietin normalized



Bilirubin decreased from 13.4 mg/dL to 1.4 mg/dL



Hepcidin increased from <4.0 ng/mL to 113.6 ng/mL




VCN in PBMCs 2.14 at 6 months and VCN in BMMCs 2.72 at 3 months post RP-L301

* Lab Values during mobilization/apheresis & post-conditioning period were not included. Most recent Hepcidin draw at 6 months.

**Data as of May 2021

RP-L301: Preliminary Efficacy Results—Patient 1002




- Hemoglobin normalized to 14.4 g/dL at ~6 months post-rx
- No red blood cell transfusion requirements following engraftment

* Lab Values during mobilization/apheresis & post-conditioning period were not included


Data as of May 2021

RP-L301: Preliminary Efficacy Results—Patient 1002


At 1–6 months post RP-L301*




Significant improvement in reticulocytes from 25.5% to 3.9%




Normalized bilirubin from 7.4 mg/dL to 1.2 mg/dL



Erythropoietin normalized



Haptoglobin normalization evident at 6 months post-RP-L301



Stable PBMC VCN of 2.55 and BMMC VCN of 2.88 at 3 months post RP-L301 infusion

Note: Recent 6-month visit data has not been monitored yet.

* Lab Values during mobilization/apheresis & post-conditioning period were not included

**Data as of May 2021

RP-L301 Conclusion: Hemoglobin Normalized in First 2 Patients

- Safety profile of RP-L301 *appears favorable*
 - Infusion well tolerated in (N=2); no IP-related serious adverse events (SAEs) at 9- and 6-months post- infusion in adult patients
 - Hematopoietic reconstitution in less than 2 weeks
 - Patients discharged from hospital within ~1 month following RP-L301 infusion
- Preliminary efficacy activity observed during initial 3-months after administration of RP-L301
 - Both patients have normalized hemoglobin, improving hemolysis markers, and no red blood cell transfusion requirements post-engraftment
 - No hospitalizations post-hospital discharge
 - Clinical improvement is associated with evidence of engraftment as measured by PB and BM VCN
- Second cohort currently open and will enroll older pediatric patients

Commercial-grade drug product and centralized testing for all treated patients

Data as of May 2021



Infantile Malignant Osteopetrosis (IMO)

Monogenic bone resorption disorder

RP-L102
Fanconi Anemia

RP-A501
Danon Disease

RP-L201
Leukocyte Adhesion Deficiency-I

RP-L301
Pyruvate Kinase Deficiency

RP-L401
Infantile Malignant Osteopetrosis

OVERVIEW:

-  **Background:** *Dysfunctional osteoclast* disease characterized by bone marrow failure, skeletal deformities, and neurologic abnormalities caused by *TCIRG1* mutations in >50% of cases¹
 - *Frequent mortality in early years of life, severe marrow failure and visual impairment during 1st year*
-  **Current Available Treatments:** Hematopoietic stem cell transplants associated with GVHD and *limited efficacy*
-  **Addressable Market:** >50 patients/year²
-  **RP-L401:** *In vitro* restoration of osteoclast resorptive function observed; *in vivo* correction in murine model
-  **Regulatory Designations:** Rare Pediatric Disease, Orphan Drug and Fast Track designations in the US


¹Source: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=667

²Estimated incidence of one in 200,000 live births; Source: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=667


Preclinical Mouse Data Supports Progression to Phase 1

Oc/Oc mice receiving RP-L401 showed correction of the disease phenotype, with increased long-term survival, tooth eruption, weight gain, and normalized bone resorption

Increased Long-term Survival



Reversal of Osteopetrotic Bone Phenotype



RP-L401 (IMO) Clinical Trial and Outcome Measures¹

Non-
Randomized
Phase 1 Study

Design

- Enroll 2 patients, with a confirmed diagnosis of IMO with documented *TCIRG1* mutation
 - 1-month or older

Primary Outcomes

- Safety associated with treatment

Secondary Outcomes

- Normalization of serum calcium and blood counts
- Presence of gene-modified blood and bone marrow cells
- Normalization of bone abnormalities on X-ray and DEXA scans
- Prevention or stabilization of vision and hearing loss
- Reduction in hepatosplenomegaly

First patient in Phase 1 Clinical Trial Dosed May 2021

¹Source: <https://www.clinicaltrials.gov/ct2/show/NCT04525352?term=NCT04525352&draw=2&rank=1>

Growing IP Portfolio



Multiple in-licensed patent families for GTx products and related technology platforms

Supporting current pipeline efforts:

- Four In-licensed pending international patent applications filed under Patent Cooperation Treaty (PCT):
 - FA (2)
 - LAD-I
 - PKD
- Multiple patent applications pending:
 - Danon (exclusive world-wide license from UCSD)
- Multiple patent families licensed from REGENXBIO:
 - Danon – AAV9 (exclusive world-wide license)
 - Danon – 2 undisclosed capsid serotypes (exclusive world-wide option to license)
- Multiple cell and gene therapy platform technologies licensed for pipeline product improvements



Rocket Proprietary Filed IP

Extensive patent portfolio across multiple platforms:

- Multiple pending patent applications for ex-vivo LVV programs
- Multiple pending patent applications for in-vivo AAV

World-Class Research and Development Partners



CIBER	IIS FJD	REGENXBIO	University of California, Los Angeles
CIEMAT	Lund University	Stanford Medical School	University of Minnesota
Fred Hutchinson Cancer Research Center	Memorial Sloan Kettering Cancer Center	UCL	University of Pennsylvania
Hospital Universitario Fundación Jiménez Díaz	Niño Jesús Hospital	University of California, San Diego	

Expansion into Cranbury, NJ: R&D/CMC Efforts and Eventual cGMP Manufacturing

2021

- Continue R&D to **further support** CMC analytics and internal QC and release testing activities for RP-A501
- 50,000 sq. ft. from this facility will be **dedicated to AAV cGMP** manufacturing (FDA and EMA compliant)
- Initiate in-house GMP clinical manufacturing
- Enables **dual-sourcing** for Danon commercial capacity



RCKT Cranbury (NJ)
103,720 sq. ft. production facility

Near and Long-Term Value Drivers

Potential for Five Gene Therapy Products to be Approved by 2025

2Q2021

3Q2021

4Q2021

✓ LAD-I: Initial Phase 2 Data

✓ FA: Updated “Process B” Data

● LAD-I: Longer-term Data

● IMO: Initial Phase 1 Data

● FA: Longer-term “Process B” Data

● PKD: Phase 1 Data Update

● Danon: Updated Phase 1 Data